Development and Optimization of Doxorubicin-Loaded Modified Chitosan Nanoparticles: A Quality by Design Approach for Enhanced Anticancer Efficacy
International Journal of Drug Delivery Technology · 16.04.2026 · 16 (14s)
DOI: 10.25258/ijddt.16.14s.22 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 16.04.2026. Verfasst von Sushama hari Garud und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Chitosan-based nanocarrier has emerged as promising drug delivery systems for cancer chemotherapy; however, their clinical translation remains limited by suboptimal drug loading, premature release, and inconsistent physicochemical properties. Chemical modification of chitosan offers opportunities to overcome these limitations through enhanced mucoadhesion, sustained release, and improved targeting capabilities.
Aim
This study aimed to synthesize and characterize a novel modified chitosan derivative and develop doxorubicin-loaded nanoparticles using a logical Quality by Design (QbD) approach to ensure robust, reproducible formulations with superior anticancer activity.
Method
Modified chitosan was synthesized and comprehensively characterized using elemental analysis, ¹H NMR, FT-IR spectroscopy, and mass spectrometry. Doxorubicin-loaded nanoparticles were prepared via the ionic gelation technique and optimized using a QbD approach. The optimized formulation was further characterized for particle size, zeta potential, X-ray diffraction (XRD), scanning and transmission electron microscopy (SEM/TEM), differential scanning calorimetry (DSC), and in vitro drug release. Anticancer activity was assessed using MTT, SRB, and XTT cytotoxicity assays, while apoptotic potential was evaluated through the trypan blue exclusion assay.
Result
Spectroscopic and analytical studies confirmed successful chemical modification of chitosan while preserving its essential functional groups. The QbD-optimized formulation (F1) exhibited favorable physicochemical characteristics, including a zeta potential of −25.3 mV, particle size of 223.4 nm, PDI of 0.019, encapsulation efficiency of 88.04%, and drug loading of 7.52%. Solid-state analyses indicated molecular dispersion of doxorubicin within the polymer matrix, confirming efficient encapsulation. The optimized nanoparticles showed pH-responsive sustained drug release (29.73% at pH 7.4 and 46.51% at pH 5.5 over 12 h) and significantly enhanced cytotoxicity in multiple cell viability assays (IC₅₀ = 70.69 µg/mL in the MTT assay), along with pronounced apoptotic induction compared to free doxorubicin, suggesting improved cellular uptake and therapeutic efficacy.
Conclusion
The modified chitosan-based nanoparticulate system developed through systematic QbD principles represents a promising platform for enhanced doxorubicin delivery with superior anticancer activity. This approach demonstrates the value of polymer modification combined with rational formulation design in advancing nanomedicine for cancer therapy.
Zitieren
APA
Garud, S. H., Jadhav, R. L., & Dharanguttikar, V. R. (2026). Development and Optimization of Doxorubicin-Loaded Modified Chitosan Nanoparticles: A Quality by Design Approach for Enhanced Anticancer Efficacy. International Journal of Drug Delivery Technology, 16(14s). https://doi.org/10.25258/ijddt.16.14s.22
Vancouver
Garud SH, Jadhav RL, Dharanguttikar VR. Development and Optimization of Doxorubicin-Loaded Modified Chitosan Nanoparticles: A Quality by Design Approach for Enhanced Anticancer Efficacy. International Journal of Drug Delivery Technology. 2026;16(14s). doi:10.25258/ijddt.16.14s.22
BibTeX
@article{Garud2026,
author = {Garud, Sushama hari and Jadhav, Rahul Laxman and Dharanguttikar, Vyaknatesh Ravindra},
title = {Development and Optimization of Doxorubicin-Loaded Modified Chitosan Nanoparticles: A Quality by Design Approach for Enhanced Anticancer Efficacy},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {14s},
doi = {10.25258/ijddt.16.14s.22}
}
EUVIMED